Swipe Left For English News
上海和圣地亚哥
2025年1月7日
全球领先的合同研究、开发和生产（CRDMO）服务公司药明生物（WuXi Biologics, 2269.HK）今日宣布与Candid Therapeutics（以下简称Candid）已达成研究服务合作协议。Candid是一家致力于成为自身免疫和炎症疾病领域T细胞衔接子（TCE）疗法领导者的临床阶段生物技术公司。
根据协议，Candid公司将拥有一款处于临床前开发阶段的三特异性抗体的全球权益。该抗体基于药明生物通用型多特异性抗体专利技术平台WuXiBody™发现。药明生物将收到一笔首付款，并有资格收到开发和销售里程碑付款，总计最高达9.25亿美元，以及产品上市后的销售提成。
陈智胜 博士
首席执行官
药明生物
我们很高兴通过WuXiBody™赋能Candid公司打造TCE疗法管线。WuXiBody™在发现双特异性抗体上的出色能力已经获得了广泛认可，此次合作不仅印证了该技术平台在发现三特异性抗体方面的卓越能力，也夯实了药明生物在新一代生物药研发合作领域中的首选地位。包括此次合作，我们的研究（R）技术平台在2024年赋能了七个分子发现服务的全球项目，有权获得总额约为1.4亿美元的近期付款，潜在总交易金额超过23亿美元。我们期待助力包括Candid在内的全球合作伙伴研发更多创新疗法，造福广大病患。
Ken Song 博士
董事长、总裁
首席执行官
Candid公司
此次合作将使我们如虎添翼，拥有三个处于或接近临床开发阶段的靶向BCMA、CD20和CD19的TCE项目，进一步巩固公司在基于B细胞耗竭的TCE疗法治疗自身免疫和炎症疾病领域的领导地位。我们很高兴与药明生物合作，充分释放该分子的治疗潜力。
基于WuXiBody™平台在双特异性抗体发现中的广泛应用，药明生物对其进行了技术升级，用于定制化发现创新多特异性抗体，以满足全球客户对这些复杂分子日益增长的研究服务需求。该平台突破了绝大多数多特异性抗体平台技术瓶颈，具有表达量高、稳定性高、溶解度好、易于纯化等优势，并且能够为每个项目节约6到18个月研发时间并显著降低多特异性抗体生产成本，实现更具成本效益和环境效益的药物开发。WuXiBody™平台几乎可将所有抗体序列用以构建多特异性抗体，并且有望降低免疫原性风险及延长其体内半衰期。WuXiBody™平台还兼具独特的灵活性，可以构建各种不同的价数（如1+1，2+2，1+1+2），以满足不同项目的生物学特性需求。
关于药明生物
药明生物（股票代码：2269.HK）是一家全球领先的合同研究、开发和生产（CRDMO）公司。公司通过开放式、一体化生物制药能力和技术赋能平台，提供全方位的端到端服务，帮助合作伙伴发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。
药明生物在中国、美国、爱尔兰、德国和新加坡拥有超过12000名员工。通过药明生物的专业服务团队，以及先进技术和精深洞见，公司为客户提供高效经济的生物药解决方案。截至2024年6月底，药明生物帮助客户研发和生产的综合项目高达742个，其中包括16个商业化生产项目（不包括新冠项目和非活跃项目）。
药明生物将环境、社会和治理（ESG）视为业务发展和企业精神的重要组成部分，并致力于成为全球生物药CRDMO领域的ESG领导者，例如应用更绿色环保的新一代生物制药技术和能源等引领行业发展。公司成立了由首席执行官领导的ESG委员会，全面落实ESG战略并践行可持续性发展承诺。更多信息，请访问：www.wuxibiologics.com。
关于
Candid Therapeutics
Candid Therapeutics是一家临床阶段的生物技术公司，致力于成为推动T细胞衔接子（TCE）疗法用于B细胞耗竭治疗自身免疫性疾病的领导者。Candid正在推进两种领先的B细胞耗竭TCE候选抗体，旨在通过靶向不同的B细胞蛋白靶标，以及评估不同深度的B细胞耗竭，广泛探索TCE在多种自身免疫性疾病中的治疗潜力。Candid成立于2024年，总部位于加利福尼亚州圣地亚哥，公司由众多具有出色的项目推进和开发经历的创业者领导，并得到了许多杰出的生命科学领域投资者的支持。
药明生物业务垂询
info@wuxibiologics.com
药明生物媒体关系
PR@wuxibiologics.com
Candid Therapeutics联系方式
Arvind Kush
info@candidrx.com
WuXi Biologics Announces Agreement with Candid Therapeutics on Trispecific T-cell Engager
SHANGHAI and SAN DIEGO
January 7, 2025
WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced an agreement with Candid Therapeutics, Inc. ("Candid"), a clinical-stage biotechnology company focused on becoming the leader in advancing T-cell engagers for autoimmune and inflammatory diseases.
Under the terms of the agreement, Candid will have exclusive global rights to a preclinical trispecific T-cell Engager discovered at WuXi Biologics' proprietary universal multispecific antibody platform WuXiBody™. WuXi Biologics is eligible to obtain an upfront payment, and development and sales milestones totaling up to $925 million as well as royalties.
Dr. Chris Chen
Chief Executive Officer
WuXi Biologics
We're glad to enable Candid to advance the progress of T-cell engagers through WuXiBody™. This collaboration not only showcases the platform's capabilities in trispecific discovery in addition to its well-validated bispecific discovery, but also reinforces WuXi Biologics' position as a preferred partner for pioneering next-generation modalities. With this collaboration, we have enabled seven global programs for molecules discovery through our Research (R) platform in 2024, and are eligible to receive around USD 140 million in near-term payments and the total potential payments exceeding USD 2.3 billion. We look forward to supporting Candid and other global partners in bringing more innovative therapies to benefit patients around the world.
Dr. Ken Song
Chairman, President and CEO
Candid
To further solidify our leadership position in T-cell engagers to deplete B cells for treatment of autoimmune and inflammatory diseases, this transaction uniquely positions us with three TCE programs targeting BCMA, CD20, and CD19 in or near clinical development. We are excited to further the advances made by WuXi Biologics and to unlock the full potential of this molecule.
Based on the widespread adoption of WuXiBody™ platform in bispecific antibody discovery, WuXi Biologics has upgraded it to deliver transformative and customized multispecific antibodies, addressing the growing global demand for these complex molecules. WuXiBody™ can effectively break through the discovery and CMC barriers for the development of many multispecific antibodies with high expression yield, high stability, good solubility, and easy purification to homogeneity, expedite the process by 6-18 months and significantly reduce manufacturing costs, limitations still faced by many other current multispecific platforms. WuXiBody™ platform enables almost any mAb sequence pairs to be assembled into multispecific constructs, which are expected to have low immunogenicity risk and longer in vivo half-life. WuXiBody™ platform also has a unique structural flexibility, which makes it convenient to build various formats with different combinations of valencies (1+1, 2+2, 1+1+2, etc.) to meet the requirements of different target biology.
About
WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2024, WuXi Biologics is supporting 742 integrated client projects, including 16 in commercial manufacturing (excluding 8 COVID CMO projects and 1 non-COVID dormant CMO project).
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com
About
Candid Therapeutics, Inc.
Candid Therapeutics is a clinical-stage biotechnology company focused on becoming the leader in advancing T-cell engagers for B-cell depletion to treat autoimmune diseases. Candid is advancing two lead B-cell depleting TCE antibody drug candidates, with a goal to broadly explore the potential of TCEs across multiple autoimmune diseases by targeting different B-cell protein targets, as well as evaluating different depths of B-cell depletion. Established in 2024 and headquartered in San Diego, CA, Candid is led by a team of entrepreneurial executives who have a track record of advancing programs into and through development and is supported by a distinguished syndicate of premier life science investors.
WuXi Biologics Contacts
-Business
info@wuxibiologics.com
-Media
PR@wuxibiologics.com
Candid Therapeutics Contacts
Arvind Kush
info@candidrx.com
注：本信息不构成药明生物的信息披露或投资建议
